americanpharmaceuticalreviewDecember 28, 2020
Tag: Tris Pharma , Neuraxpharm , ADHD
Tris Pharma and Neuraxpharm Group have entered into an agreement whereby Neuraxpharm received exclusive rights to commercialize Tris' FDA-approved Quillivant XR and Quillichew ER in Europe.
"We are excited to add Tris' differentiated ADHD medications to our CNS portfolio," said Dr. Jörg-Thomas Dierks, Neuraxpharm's CEO. "Both products offer a unique clinical profile, addressing the challenges experienced by many younger ADHD patients who have difficulty swallowing pills and finding an optimal dose. Tris' one-of-a-kind long-acting once-daily liquid and chewable methylphenidate products will offer additional options to such patients in Europe, enabling a more acceptable dosage form while allowing for improved dosing customization.”
"As one of the largest pharmaceutical markets in the world, Europe has been a high priority for Tris as we continue to strive to make our differentiated product portfolio available to patients globally," said Ketan Mehta, Tris' Founder and CEO. "Neuraxpharm has broad commercial reach in Europe and has established a leadership position with its portfolio of CNS medications. With its unique and highly relevant track record with differentiated formulations in the European market, we believe they are an excellent partner to maximize the value of our products to both companies as well as to patients."
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: